Pharmacotherapy of mania: A review

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 3, 2000, Pages 171-193

  Segal, J ^a   Walton, S ^a   Clark, H ^a   Berk, M ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Anticonvulsants; Antipsychotics; Bipolar disorder; Mania; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DILTIAZEM; DROPERIDOL; FELBAMATE; FLUNARIZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; OLANZAPINE; OXCARBAZEPINE; OXPRENOLOL; PARALDEHYDE; PROPRANOLOL; QUETIAPINE; REMACEMIDE; RISPERIDONE; SERTINDOLE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL; VIGABATRIN; ZIPRASIDONE; ZONISAMIDE; ZUCLOPENTHIXOL;

ATAXIA; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DYSARTHRIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; MANIA; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; TRANQUILIZING ACTIVITY; VERTIGO;

EID: 0033825971     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500050518064     Document Type: Review

References (348)

1. Lithium: The present and the future
2. Bipolar disorder: Epidemiology, cause, diagnosis and treatment
3. Practice guideline for the treatment of patients with bipolar disorder
4. Lithium in the treatment of mood disorders
5. Key treatment studies of lithium in manic depressive illness: Efficacy and side effects
6. Current therapeutic profile of lithium
7. The treatment of manic psychoses by the administration of lithium salts
8. Treatment of manic illness with lithium carbonate
9. Lithium carbonate treatment in depression and mania: A longitudinal double blind study
10. Efficacy of lithium as acute treatment of manic-depressive illness
11. Recent advances in treatment of acute mania
12. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states
13. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states
14. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group
15. Psychoactive drugs in mania: A controlled comparison of lithium carbonate, chlorpromazine and haloperidol
16. Lithium and chlorpromazine in psychotic inpatients
17. Comparison of efficacy of lithium carbonate and chlorpromazine in mania
18. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania
19. A comparison of lithium carbonate and chlorpromazine in mania
20. A quantitative analysis of clinical trials for the treatment of affective disorders
21. Lithium compared to valproic acid and carbamazepine in the treatment of mania: A statistical meta-analysis
22. Carbamazepine compared with lithium in the treatment of mania
23. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study
24. Carbamazepine vs lithium in the treatment and prophylaxis of mania
25. Carbamazepine versus lithium in mania: A double-blind study
26. Efficacy of divalproex, lithium and placebo in the treatment of mania
27. A double-blind comparison of valproate and lithium in the treatment of acute mania
28. The treatment of mania: A retrospective evaluation of the effects of electroconvulsive therapy, chlorpromazine and lithium
29. Treatment of mania: A naturalistic study of electroconvulsive therapy versus lithium in 438 patients
30. Electroconvulsive treatment compared with lithium in the management of manic states
31. Drug treatment of mania: A critical review
32. The challenge of predicting response to stabilising lithium treatment
33. Has the effectiveness of lithium changed? Impact of the variety of lithium's effects
34. Lithium: Evidence reconsidered
35. Lithium: Balancing risks and benefits
36. Non-lithium treatment for bipolar disorder
37. Secondary mania: Diagnosis and treatment
38. The manic syndrome: Factors which may predict a patient's response to lithium, carbamazepine and valproate
39. Predictors of response to divalproex and lithium
40. Lithium treatment of mania: Clinical characteristics, specificity of symptom change and outcome
41. Treatment of acute mania
42. Lithium: The present and the future
43. A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar disorder
44. Lithium
45. Dosing strategies and time course of response to antimanic drugs
46. Treatment of manic episodes: Zuclopenthixol and clonazepam versus lithium and clonazepam
47. Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment
48. Comparison of therapeutic modalities of mania
49. Lithium combined with carbamazepine or haloperidol in the treatment of mania
50. Lithium: A therapeutic magic wand
51. Safety of the combination of lithium and neuroleptic drugs
52. Newer medications for bipolar disorder
53. Antipsychotic agents and bipolar disorder
54. Role of neuroleptics in manic depressive illness
55. Neuroleptics in acute mania: A pharmacoepidemiologic study
56. Treatment algorithm to optimize management of symptomatic patients with a history of mania
57. The expert consensus guideline series: Treatment of bipolar disorder
58. Mania, psychosis and antipsychotics
59. Antipsychotics in bipolar disorder
60. Anticonvulsants and antipsychotics in the treatment of bipolar disorder
61. Emergency treatment of acute psychosis
62. The role of antipsychotics in the treatment of bipolar disorder patients
63. Treatment of manic episodes in Scandinavia: The use of neuroleptic drugs in a clinical routine setting
64. Approaches to the evaluation and treatment of rapid cycling affective illness
65. Adjuncts and alternative to lithium therapy for bipolar affective disorder
66. Depot antipsychotics in the prophylaxis of bipolar affective disorder
67. Toxic reaction to lithium and neuroleptics
68. Neurotoxicity with combined use of lithium and thioridazine
69. Lithium interactions with other drugs
70. Lithium carbonate - Fluphenazine decanoate producing irreversible brain damage
71. Lithium carbonate, haloperidol and irreversible brain damage
72. Toxic reactions to lithium and haloperidol
73. New data on lithium and haloperidol incompatibility
74. Haloperidol and lithium: Their combined use and the issue of their compatibility
75. Electroencephalographic changes and other indices of neurotoxicity with haloperidol lithium therapy
76. A placebo controlled study of lithium combined with neuroleptics in chronic schizophrenic patients
77. Combination of lithium carbonate and haloperidol in schizoaffective disorder: A controlled study
78. Lithium combined with neuroleptics in chronic schizophrenia and schizoaffective patients
79. Advances in the treatment of mania and related disorders: A reappraisal
80. Antimanic effects of clonazepam
81. The use of benzodiazepines in the treatment of manic depressive illness
82. Use of benzodiazepines to improve the management of manic agitation
83. Valproate as a loading treatment in acute mania
84. Valproate oral loading in the treatment of acute mania
85. A randomized comparison of divalproex oral loading vs haloperidol in the initial treatment of acute psychotic mania
86. An open trial of carbamazepine in treatment resistant bipolar and schizoaffective psychotics
87. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders
88. Refractory manias and alternatives to lithium treatment
89. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder
90. Psychosis after neuroleptic withdrawal in a manic-depressive patient
91. Neuroleptic induced supersensitivity psychosis in patients with bipolar affective disorder
92. Severe cases of neuroleptic induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment
93. The concept of supersensitivity psychosis
94. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic induced supersensitivity psychosis and refractory schizophrenia
95. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics
96. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
97. Tardive dyskinesia: Prevalence and risk factors
98. Persistent tardive dyskinesia in bipolar patients
99. Higher frequency of neuroleptic induced dystonia in mania than in schizophrenia
100. Risk factors for neuroleptic malignant syndrome: A case-control study
101. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic
102. Understanding the mechanism of action of atypical antipsychotic drugs: A review of compounds in use and development
103. The relationship of pharmacology to side effects
104. Seroquel: A putative atypical antipsychotic drug with serotonin and dopamine receptor antagonist properties: Preclinical and early clinical trials in schizophrenia
105. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics
106. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents
107. Effects of antipsychotic drugs on serotonin receptors
108. The atypical antipsychotic sertindole: A case series
109. Establishing cost-effectiveness of atypical neuroleptics
110. Formulary decisions and health economics
111. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia
112. Clozapine increases dopamine release in prefrontal cortex by 5HT(1A) receptor activation
113. Is clozapine a mood stabilizer?
114. Clozapine in severe mood disorders
115. Uses of clozapine in non-schizophrenic patients
116. Clozapine therapy in refractory affective disorders: Polarity predicts response in long term follow up
117. Risperidone: Neurochemical pharmacologic and clinical properties of a new antipsychotic drug
118. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: A functional approach
119. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
120. Risperidone in HIV-related manic psychosis
121. Hypomania associated with risperidone
122. Behavioral stimulation associated with risperidone initiation
123. Mania associated with risperidone use
124. Risperidone and mania
125. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania
126. The use of risperidone in the treatment of bipolar disorder
127. Probable induction of mania by risperidone
128. Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient
129. Risperidone monotherapy for psychotic depression unresponsive to other treatments
130. Risperidone treatment of refractory acute mania
131. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
132. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders
133. Efficacy of risperidone treatment for psychosis associated with schizophrenia, schizoaffective disorder, bipolar disorder or senile dementia in 77 geriatric patients: A case series
134. Risperidone in treatment of mania
135. Risperidone compared with both lithium and haloperidol in mania: A double blind randomized controlled trial
136. Mania induced by risperidone: Dose related?
137. Risperidone and tardive dyskinesia: A case report
138. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects?
139. Withdrawal emergent dyskinesia in a patient on risperidone undergoing dosage reduction
140. Risperidone induced tardive dyskinesia
141. Neuroleptic induced tardive dyskinesia
142. Risperidone and tardive dyskinesia
143. Risperidone induced tardive dyskinesia and parkinsonism
144. Tardive dyskinesia induced by risperidone?
145. Progression of abnormal involuntary movements during risperidone treatment
146. In vitro and in vivo biochemistry of olanzapine: A novel atypical antipsychotic drug
147. Behavioural pharmacology of olanzapine, a novel antipsychotic drug
148. Efficacy of olanzapine: An overview of pivotal clinical trials
149. Efficacy of olanzapine: An overview of pivotal clinical trials
150. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
151. Safety of olanzapine
152. Olanzapine and the new generation of antipsychotic agents: Patterns of use
153. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
154. Clinical predictors of acute response with olanzapine in psychotic mood disorders
155. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
156. A placebo controlled trial of olanzapine in psychotic or non psychotic acute mania
157. Management of acute mania
158. Olanzapine induced manic like syndrome
159. Olanzapine response in psychotic depression
160. Sertindole, a new antipsychotic drug
161. Controlled dose response study of sertindole and haloperidol in the treatment of schizophrenia
162. Schizoaffective disorder and psychotic mania
163. Polypharmacy in bipolar disorder
164. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
165. Ziprasidone (CP-88, 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
166. The efficacy and the use of anticonvulsants in mood disorders
167. Use of carbamazepine in acute psychosis: A controlled study
168. Treatment of mixed mania
169. Effects of carbamazepine and lithium on affective disorders
170. Prophylaxis of bipolar affective disorder
171. Trends in pharmacotherapy of schizoaffective and bipolar affective disorder: A 5-year naturalistic study
172. On the possible role of GABA in mania: Therapeutic efficacy of sodium valproate
173. Valproate in the treatment of acute mania: A placebo controlled study
174. Use of sodium valproate in the management of affective disorders: Basic and clinical aspects
175. Depression during mania: Treatment response to lithium or divalproex
176. Mixed or dysphoric manic states: Psychopathology and treatment
177. Predictors of valproate response in bipolar rapid cycling
178. Dysphoric or mixed mania and hypomania: Clinical and research implications
179. Treatment of psychiatric disorders with valproate: A series of 73 cases
180. Spectrum of efficacy of valproate in 78 rapid cycling bipolar patients
181. Treatment of rapid cycling bipolar disorder with sodium valproate
182. The relationship between substance abuse and bipolar disorder
183. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels
184. Cell type-dependent effect of sodium valproate on human immunodeficiency type 1 replication in vitro
185. Sodium valproate, an anticonvulsant drug, stimulates cytomegalovirus replication
186. Valproic acid treatment of AIDS-related mania
187. Possible risks associated with valproate treatment of AIDS-related mania
188. Factors predicting the use of multiple psychotropic medications
189. Mood stabilizer combinations: A review of safety and efficacy
190. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium
191. Myristolated alanine-rich C kinase substrate (MARCKS): A molecular target for the therapeutic action of mood stabilizers in the brain?
192. Lithium and carbamazepine interaction: Possible neurotoxicity
193. Asterixis induced by carbamazepine therapy
194. Cytochrome P450 isoenzymes and antiepileptic drug interactions
195. Carbamazepine auto induction and hereto-induction complicating clinical care
196. Pharmacological issues in the treatment of bipolar disorder: Focus on mood stabilizing compounds
197. Synergy of carbamazepine and valproic acid in affective illness: Case report and review of the literature
198. A double blind placebo controlled study of lamotrigine monotherapy in out patients with bipolar I depression
199. New antiepileptic drugs: A systematic review of their efficacy and tolerability
200. Analysis based on the number needed to treat shows differences between drugs studied
201. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers
202. First dose steady state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite
203. Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance: Comparison with carbamazepine
204. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders
205. GP47779, the main human metabolites of oxcarbazepine (Trileptal) and both enantiomers have equal anticonvulsant activity
206. Antiepileptic drug mechanisms of action
207. Studies with oxcarbazepine (Trileptal) in acute mania
208. Anticonvulsants in the treatment of bipolar disorder
209. The place of anticonvulsant therapy in bipolar illness
210. Carbamazepine and oxcarbazepine in the treatment of manic syndromes, studies in Germany
211. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders
212. Clobazam, oxcarbazepine, tiagabine, topiramate and other new antiepileptic drugs
213. Lamotrigine
214. Outcomes of add-on treatment with lamotrigine in partial epilepsy
215. Lamotrigine
216. Lamotrigine
217. Perspectives on lamotrigine
218. Lamotrigine: An antiepileptic agent for the treatment of partial seizures
219. The new generation of antiepileptic drugs; advantages and disadvantages
220. Role of the new and established antiepileptic drugs
221. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs
222. The anticonvulsant lamotrigine in treatment resistant manic depressive illness
223. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder
224. An open study of lamotrigine in refractory bipolar depression
225. Lamotrigine in the treatment of resistant bipolar disorder
226. Gabapentin
227. Gabapentin
228. Movement disorders associated with the use of gabapentin
229. Characterization of [3H]-gabapentin binding to a novel site in rat brain: Homogenate binding studies
230. Treatment of acute mania with gabapentin
231. Gabapentin in the treatment of bipolar disorder
232. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder
233. Gabapentin in the treatment of adolescent mania: A case report
234. Clinical experience using gabapentin in patients with a history of mania or hypomania
235. Acute treatment of bipolar depression with gabapentin
236. Hypomania induced by gabapentin
237. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant
238. Topiramate: A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
239. Safety of topiramate: Adverse events and relationships to dosing
240. Severe psychiatric reactions to topiramate
241. Zonisamide in epilepsy: A pilot study
242. Neuropharmacology of zonisamide, a new antiepileptic drug
243. Efficacy and safety of zonisamide: Results of a multicentre study
244. Zonisamide (CI-912) and cognition: Results from a preliminary study
245. The first open study of zonisamide, a novel anticonvulsant shows efficacy in mania
246. Felbamate
247. Felbamate
248. Felbamate: 1997 Update
249. Secondary mania associated with the use of felbamate
250. Felbamate monotherapy has stimulant like effects in patients with epilepsy
251. Felbamate: Current practice options
252. Vigabatrin
253. Update on the mechanisms of action of antiepileptic drugs
254. Vigabatrin in drug resistant partial epilepsy: A 5-year follow up study
255. Vigabatrin
256. Vigabatrin and behavior disturbances
257. Pharmacokinetics of tiagabine, a GABA-amino-butyric acid uptake inhibitor, in healthy subjects after single and multiple doses
258. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor
259. Tiagabine pharmacology in profile
260. Tiagabine: The safety landscape
261. Effects of tiagabine monotherapy on abilities, adjustment and mood
262. Remacemide hydrochloride and ARL 15896AR lack abuse potential; Additional differences from the uncompetitive NMDA antagonists
263. A controlled trial of remacemide hydrochloride in Huntington's disease
264. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist in rodent and primate models of Parkinson's disease
265. Rational polypharmacy
266. Lamotrigine induced carbamazepine toxicity: An interaction with carbamazepine 10,11-epoxide
267. Efficacy of lamotrigine in bipolar disorder: Preliminary data
268. Lack of interactions of gabapentin with carbamazepine or valproate
269. Bidirectional interaction of valproate and lamotrigine in healthy subjects
270. Do calcium antagonists have a place in the treatment of mood disorders?
271. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder
272. Verapamil in affective disorders: A controlled double blind study
273. Effectiveness of verapamil in the treatment of a manic patient
274. Phenelzine-induced hypomania: Effect of verapamil
275. Verapamil and valproic acid treatment of prolonged mania
276. Treatment of acute mania with verapamil
277. Refractory bipolar illness may not respond to verapamil
278. Experience with verapamil (Isoptin Knoll) in psychiatry
279. Verapamil treatment of acute mania
280. Verapamil in treatment-resistant mania: An open trial
281. Cortisol, prolactin and growth hormone levels with clinical ratings in manic patients treated with verapamil
282. Antimanic effects of verapamil
283. Comparison of the antimanic effect of clonidine and verapamil
284. Use of calcium antagonists in mania
285. Calcium antagonists in mania: A double-blind study of verapamil
286. Verapamil in affective disorders: A controlled double blind study
287. Verapamil versus lithium in acute mania
288. Superiority of lithium over verapamil in mania: A randomised, controlled, single-blind trial
289. Verapamil for the treatment of acute mania: A double-blind, placebo-controlled trial
290. Open trial of a calcium antagonist, nimodipine, in acute mania
291. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation
292. Treatment of mania using a calcium antagonist - Preliminary trial
293. Treatment of neuroleptic resistant mania and schizoaffective disorders
294. Depression associated with nifedipine-induced calcium channel blockade
295. Calcium channel blockade and depressive illness
296. Flunarizine as maintenance treatment of a patient with bipolar disorder
297. Calcium antagonists in manic depressive illness
298. Verapamil: A new antimanic drug with potential interactions with lithium
299. Psychiatric indications for clonidine: The neuropharmacologic and clinical basis
300. Treatment of acute mania
301. Comparison of clonidine and lithium in the treatment of mania
302. Antimanic effect of clonidine
303. Clonidine in the treatment of mania and mixed bipolar disorder
304. Clonidine. An effective antimanic agent?
305. Efficacy of clonidine in 24 patients with acute mania
306. The effect of clonidine in the treatment of acute mania
307. Comparison of clonidine and lithium in the treatment of mania
308. Comparison of antimanic efficacy of clonidine and verapamil
309. A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania
310. Psychiatric uses of anti adrenergic and adrenergic blocking drugs
311. New drugs for mania?
312. Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 cases
313. The effect of the beta-adrenergic blocking agent propranolol in mania
314. Action of propranolol in mania: Comparison of effects of the d- and the l-stereoisomer
315. Adjuncts and alternatives to lithium therapy for bipolar affective disorder
316. Clonazepam in acute and maintenance treatment of bipolar disorder
317. Clonazepam a novel therapeutic adjunct
318. Benzodiazepines: Abuse and new use
319. A randomised controlled single blind study of the efficacy of clonazepam and lithium in the treatment of acute mania
320. Use of clonazepam in two cases of acute mania
321. Use of clonazepam in mania and schizoaffective disorders
322. Clonazepam in acute mania: A double blind trial
323. Clonazepam in acute mania: Time-blind evaluation of clinical response and concentrations in plasma
324. Therapeutic drug monitoring of anticonvulsants
325. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania
326. Clonazepam in the treatment of steroid-induced mania in a patient after renal transplantation
327. A case of mania secondary to hemodialysis: Successful treatment with clonazepam
328. Emerging uses for high-potency benzodiazepines in psychotic disorders
329. Intramuscular lorazepam to restrain violent patients
330. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study
331. A comparison of two adjunctive treatment strategies in acute mania
332. In-patient clinical trial of lorazepam for the management of manic agitation
333. Clonazepam treatment of five lithium refractory patients with bipolar disorder
334. Use of clonazepam for bipolar affective disorder
335. Dependence on benzodiazepines
336. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity
337. Antianxiety therapy: Potential value of long term treatment
338. Abuse of benzodiazepines: The problems and the solutions. A report of a committee of the Institute for Behaviour and Health, Inc.
339. Risks and benefits of long term benzodiazepine use
340. Clonazepam and lithium: A toxic combination in the treatment of mania?